4DMedical posts FY26 revenue growth as commercial deployment ramps up
4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major healthcare partnerships.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| VXR | Change of Director's Interest Notice | 18/04/18 | ||
| VXR | Change of Director's Interest Notice-Appendix 3Y x 3 | 16/04/18 | ||
| VXR | March 2018 Quarterly Cashflow Report | PRICE SENSITIVE | 11/04/18 | |
| VXR | March 2018 Quarterly Activities Report | PRICE SENSITIVE | 11/04/18 | |
| VXR | Initial Director's Interest Notice | 05/04/18 | ||
| VXR | Appointment of Managing Director | 05/04/18 | ||
| VXR | Whim Creek Project Resources Update | PRICE SENSITIVE | 23/03/18 | |
| VXR | Sulphur Springs Resource Upgrade | PRICE SENSITIVE | 21/03/18 | |
| VXR | Euroz Rottnest Forum Presentation | 15/03/18 | ||
| VXR | VXR Interim Financial Report Ending 31 December 2017 | 14/03/18 | ||
| VXR | Expiry of Performance Rights | 02/03/18 | ||
| VXR Change of Director's Interest Notice | |||
| 18/04/18 | |||
| VXR Change of Director's Interest Notice-Appendix 3Y x 3 | |||
| 16/04/18 | |||
| VXR March 2018 Quarterly Cashflow Report | |||
| 11/04/18 | PRICE SENSITIVE | ||
| VXR March 2018 Quarterly Activities Report | |||
| 11/04/18 | PRICE SENSITIVE | ||
| VXR Initial Director's Interest Notice | |||
| 05/04/18 | |||
| VXR Appointment of Managing Director | |||
| 05/04/18 | |||
| VXR Whim Creek Project Resources Update | |||
| 23/03/18 | PRICE SENSITIVE | ||
| VXR Sulphur Springs Resource Upgrade | |||
| 21/03/18 | PRICE SENSITIVE | ||
| VXR Euroz Rottnest Forum Presentation | |||
| 15/03/18 | |||
| VXR VXR Interim Financial Report Ending 31 December 2017 | |||
| 14/03/18 | |||
| VXR Expiry of Performance Rights | |||
| 02/03/18 | |||